Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 6, 2011, Pages 358-364

  Pang, Wei ^a   Li, Nan ^a   Ai, Ding ^a   Niu, Xiao Lin ^b   Guan, You Fei ^a   Zhu, Yi ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Angiotensin II; Hypertrophy; Peroxisome proliferator activated receptor ; Soluble epoxide hydrolase; Thiazolidinediones

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; EPOXIDE HYDROLASE; MYOSIN HEAVY CHAIN BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; MALE; MOUSE; NEWBORN; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CELL LINE; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIGANDS; MALE; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PPAR GAMMA; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 79956311708     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05492.x     Document Type: Article

References (40)

1. Ho YL, Wu CC, Lin LC et al. Assessment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropine stress echocardiography: Effect of the left ventricular hypertrophy. Cardiology 1998; 89: 52-8.
2. Dorn GW II, Robbins J, Sugden PH. Phenotyping hypertrophy: Eschew obfuscation. Circ. Res. 2003; 92: 1171-5.
3. Chien KR. Stress pathways and heart failure. Cell 1999; 98: 555-8.
4. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Prog. Lipid Res. 2004; 43: 55-90.
5. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002; 82: 131-85.
6. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 2001; 276: 36059-62.
7. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N. Engl. J. Med. 2007; 357: 1121-35.
8. Fang X, Weintraub NL, McCaw RB et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H2412-20.
9. Ai D, Pang W, Li N et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc. Natl Acad. Sci. USA 2009; 106: 564-9.
10. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 2000; 129: 823-34.
11. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertension. Hypertension 2003; 42: 664-8.
12. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 1997; 272: 8071-6.
13. Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: What is the evidence? Diab. Vasc. Dis. Res. 2005; 2: 61-6.
14. Nakamoto M, Ohya Y, Shinzato T et al. Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension. Hypertens. Res. 2008; 31: 353-61.
15. Nilsson PM, Hedblad B, Donaldson J, Berglund G. Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance. Blood Press. 2007; 16: 95-100.
16. Asakawa M, Takano H, Nagai T et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-6.
17. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 2008; 10: 1221-38.
18. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl Acad. Sci. USA 2000; 97: 1196-201.
19. Hao GH, Niu XL, Gao DF, Wei J, Wang NP. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br. J. Pharmacol. 2008; 153: 1409-19.
20. Jones JR, Shelton KD, Guan Y, Breyer MD, Magnuson MA. Generation and functional confirmation of a conditional null PPARgamma allele in mice. Genesis 2002; 32: 134-7.
21. Akiyama TE, Sakai S, Lambert G et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 2002; 22: 2607-19.
22. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 2004; 25: 331-6.
23. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670-5.
24. Takano H, Hasegawa H, Nagai T, Komuro I. The role of PPARgamma-dependent pathway in the development of cardiac hypertrophy. Drugs Today 2003; 39: 347-57.
25. Sakai S, Miyauchi T, Irukayama-Tomobe Y, Ogata T, Goto K, Yamaguchi I. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin. Sci. 2002; 103 (Suppl 48): 16S-20S.
26. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007; 356: 2457-71.
27. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-35.
28. Bach RG. Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the BARI 2D Trial. American Diabetes Association (ADA) 2010 Scientific Sessions, Orlando, FL. 2010.
29. Fang X, Kaduce TL, Weintraub NL et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem. 2001; 276: 14867-74.
30. Fang X, Kaduce TL, Weintraub NL, Spector AA. Cytochrome P450 metabolites of arachidonic acid: Rapid incorporation and hydration of 14, 15-epoxyeicosatrienoic acid in arterial smooth muscle cells. Prostaglandins Leukot. Essent. Fatty Acids 1997; 57: 367-71.
31. Jung O, Brandes RP, Kim IH et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005; 45: 759-65.
32. Ulu A, Davis BB, Tsai HJ et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J. Cardiovasc. Pharmacol. 2008; 52: 314-23.
33. Motoki A, Merkel MJ, Packwood WH et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 2008; 295: H2128-34.
34. Monti J, Fischer J, Paskas S et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet. 2008; 40: 529-37.
35. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002; 39: 690-4.
36. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 2007; 47: 87-98.
37. Xu D, Li N, He Y et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl Acad. Sci. USA 2006; 103: 18733-8.
38. Ai D, Fu Y, Guo D et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA 2007; 104: 9018-23.
39. Wang N, Verna L, Chen NG et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 2002; 277: 34176-81.
40. Zhang D, Ai D, Tanaka H, Hammock BD, Zhu Y. DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1 dependent mechanism. Biochim. Biophys. Acta 2010; 1799: 659-67.